ClinicalTrials.Veeva

Menu

EndoMAXX Endoluminal Valve Technology (EVT) Compared to EndoMAXX

M

Merit Medical Systems

Status

Completed

Conditions

Malignant Esophageal Strictures

Treatments

Device: EndoMAXX
Device: EndoMAXX Endoluminal Valve Technology (EVT)

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT02159898
ESO-P3-12-02

Details and patient eligibility

About

This is a prospective, single blinded, randomized study of EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve for the treatment of malignant strictures of the lower esophagus. The purpose of this study is to evaluate improvement of dysphagia due to esophageal stricture with EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve (investigational device) compared to the EndoMAXX Fully Covered Esophageal Stent (reference device).

Enrollment

60 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patient is 18 years of age or older
  2. Patient (or legal representative) is able to understand and provide signed informed consent
  3. Patient has a malignant stricture of the distal esophagus or gastric cardia requiring stent placement across the gastroesophageal junction.

Exclusion criteria

  1. Patient is unwilling or unable to comply with the follow-up schedule
  2. Patient is contraindicated for endoscopic procedure for any reason
  3. Patient presents with esophagorespiratory fistula
  4. Patient has previously undergone esophageal stenting or esophagectomy
  5. Female patient is pregnant, breastfeeding, or premenopausal and not using an effective method of contraception
  6. Patient's esophageal tumor length exceeds that which can be treated with a single stent (maximum lesion length 9.5cm)
  7. Removal of stent is scheduled to occur within six months
  8. Patient has trouble swallowing or experiences regurgitation for reasons which are not related to his/her esophageal cancer
  9. Any other factor identified by the Investigator that would disqualify the prospective patient from participation in the study including but not limited to coagulative disorders and anesthetic risk.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

60 participants in 2 patient groups

EndoMAXX Endoluminal Valve Technology (EVT)
Experimental group
Description:
EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve
Treatment:
Device: EndoMAXX Endoluminal Valve Technology (EVT)
EndoMAXX
Active Comparator group
Description:
EndoMAXX Fully Covered Esophageal Stent
Treatment:
Device: EndoMAXX

Trial contacts and locations

7

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems